Cardiff Oncology Logo
US14147L1089
A2P4GU
CRDF

Cardiff Oncology

Prévisions

L'objectif de cours moyen des analystes est de 1,82 € (+127,50 %). La médiane est de 1,82 € (+127,50 %).

Acheter
  8
Conserver
  6
Vendre
  1

Discussions dans la communauté

Il n'y a pas encore de discussion sur cet actif.

Lancer une discussion

  • Cardiff Oncology outlines phase III plan for Onvansertib, financing open

    Cardiff Oncology confirmed exclusive worldwide rights to Onvansertib after an agreement with Nerviano and presented convincing phase II data at an investor conference, reporting an overall response rate of 72% for the Onvansertib plus FOLFIRI/Bevacizumab combination. The FDA agreed to a simplified 1:1 randomized phase III design (CRDF‑004) with about 640 patients, with overall response rate as the primary endpoint potentially enabling accelerated approval. The company is targeting a global launch in early 2026 but still needs to secure $128–176 million to fund the trial and is weighing capital‑markets options, non‑dilutive financings and partnerships. » Plus sur de.investing.com


  • Cardiff Oncology secures $10 million in registered direct offering

    Cardiff Oncology completed the sale of 8,571,429 shares of common stock and accompanying warrants at $1.05 each in a registered direct offering, yielding gross proceeds of approximately $10 million before fees. Officers and directors purchased 731,707 shares and warrants at $1.435 each; the warrants have an exercise price of $1.31, are exercisable no earlier than six months after issuance or after approval of the equity increase, and expire five and a half years after they first become exercisable. H.C. Wainwright & Co. acted as exclusive placement agent. Cardiff Oncology intends to use the net proceeds for working capital and general corporate purposes. » Plus sur de.investing.com


  • Cardiff Oncology presents preclinical Onvansertib data at AACR meeting

    Cardiff Oncology will present preclinical data on its PLK1 inhibitor Onvansertib at the AACR 2026 annual meeting, which are intended to show that Onvansertib enhances the antitumor activity of trastuzumab‑deruxtecan (T‑DXd) and overcomes resistance in treatment‑refractory HER2‑low breast cancer models. Onvansertib is an orally administered PLK1 inhibitor currently being tested in a phase 2 trial in RAS‑mutant metastatic colorectal cancer and is being investigated in additional trials across various tumor types. The poster (abstract no. 329) will be made available on the company’s website after the presentation. » Plus sur de.investing.com


  • Cardiff Oncology presents strong phase‑2 data for onvansertib in RAS‑mutant colorectal cancer

    Onvansertib, combined with FOLFIRI and bevacizumab, showed an overall response rate of 72.2%, well above the 42% benchmark. Cardiff plans a global phase‑3 trial at 30 mg in the first half of 2026, subject to discussions with the FDA. The company has $58.3 million in cash, which is expected to fund operations until early 2027 but does not cover the anticipated costs of the phase‑3 trial. Pfizer invested $15 million and is serving as a CRO partner; Cardiff retains full rights to the program, is exploring additional indications, and anticipates regulatory and financial challenges. » Plus sur de.investing.com


  • Cardiff Oncology stock plunges after phase 2 update on Onvansertib

    Cardiff Oncology reported that Onvansertib combined with FOLFIRI/Bevacizumab showed dose-dependent higher overall response rates; the 30 mg group achieved a confirmed ORR of 72.2% versus 43.2% with standard therapy, and progression-free survival has not yet been reached. Despite the positive assessment and the announcement to advance the 30 mg dose into a registrational trial, shares fell about 30% in premarket trading — investors appeared disappointed, apparently due to expectations of stronger signals or concerns about statistical significance. Onvansertib was well tolerated; the most common adverse event was neutropenia. The company appointed an interim CEO and announced personnel changes in finance, and said it will present final data and a plan for the registrational study in H1 2026 in coordination with the FDA. » Plus sur de.investing.com

Données financières

Au dernier trimestre, Cardiff Oncology a réalisé un chiffre d'affaires de 150,97 k € et un bénéfice net de -7,82 M €

(EUR) septembre 2026
YoY
Chiffre d'affaires 150,97 k 47,64 %
Bénéfice brut -8,14 M 8 059,46 %
Bénéfice net -7,82 M 18,49 %
EBITDA -7,74 M 15,60 %

Données fondamentales

Indicateur Valeur
Capitalisation boursière
59,4 M €
Nombre d'actions
77,8 M
Plus haut/bas sur 52 semaines
3,01 € - 0,65 €
Dividendes Non
Bêta
1,56
Ratio P/E
-1,53
Ratio PEG
-0,03
Ratio P/B
2,27
Ratio P/S
116,76

Profil de l'entreprise

Cardiff Oncology, Inc., une société d'oncologie au stade clinique, développe des traitements médicamenteux destinés aux patients atteints de cancer en Californie. Son principal candidat-médicament est l'onvansertib, un inhibiteur oral sélectif de la kinase 1 de type Polo (Polo-like Kinase 1) destiné aux thérapies anticancéreuses ; le CY140, un inhibiteur de PLK1, PLK2 et PLK3 actuellement en études de phase 1/2 sur les tumeurs solides et les leucémies ; le cancer colorectal métastatique, faisant l'objet d'essais cliniques ; et le TROV-054, un produit en phase 1b/2 associé à FOLFIRI et au bevacizumab. Le TROV-053 de la société fait également l'objet d'un essai clinique de phase II en association avec Zytiga pour le traitement du cancer de la prostate métastatique résistant à la castration. La société sert principalement les fabricants pharmaceutiques. La société était précédemment connue sous le nom de Trovagene, Inc. et a changé de nom pour devenir Cardiff Oncology, Inc. en mai 2012. Cardiff Oncology, Inc. a été constituée en 1999 et son siège social se situe à San Diego, en Californie.

Nom
Cardiff Oncology
PDG
Mani Mohindru
Siège social San Diego, ca
États-Unis
Site web
Secteur
Consommation de base
Industrie
Produits alimentaires
Introduction en bourse
27/07/2004
Employés 31

Symboles boursiers

Bourse Symbole
NASDAQ
CRDF
Frankfurt
XE7C.F
Düsseldorf
XE7C.DU
München
XE7C.MU
🍪

Parqet  utilise des cookies. En savoir plus